Shares of Bicara Therapeutics (BCAX) (BCRX) after moving lower after Johnson & Johnson (JNJ) reported Phase 1b/2 data for amivantamab in patients with head and neck squamous cell carcinoma. J&J’s data show tumor shrinkage was observed in 82% of patients. Bicara is developing ficerafusp alfa combined with pembrolizumab as a treatment for head and neck squamous cell carcinoma. The stock in midday trading is down 20% to $14.52.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Bicara Therapeutics management to meet with Cantor Fitzgerald
- Bicara Therapeutics announces ficerafusp alfa granted BTD by U.S. FDA
- Bicara Therapeutics files $400M mixed securities shelf
- Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
- Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside